OXFORD, United Kingdom, Jan. 29, 2026 (GLOBE NEWSWIRE) -- Scancell Holdings plc (AIM: SCLP), the developer of ImmunoBody® and Moditope® active immunotherapies…
MESA, ARIZONA / ACCESS Newswire / January 28, 2026 / Medical Care Technologies Inc. (OTC PINK:MDCE) ("MDCE" or the "Company"),…
Interim results from Phase 2b clinical trial of RAD 101 showed 92% of evaluable participants met the primary endpoint of…
Newly Appointed President & Chief Executive Officer, Rami Levin, Discusses Plans for a New Era at CNS PharmaceuticalsStrategic Focus, Pipeline…
Phio's Presentation to take place on Wednesday January 28, 2026 at 9 AM ETKing of Prussia, Pennsylvania--(Newsfile Corp. - January…
SAN DIEGO, Jan. 26, 2026 (GLOBE NEWSWIRE) -- Today, Primmune Therapeutics, a biotech company harnessing the power of the innate…
Expands CNSide Clinical License in State of PennsylvaniaHOUSTON, Jan. 22, 2026 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (NASDAQ: PSTV) (the…
HOUSTON, Jan. 21, 2026 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (NASDAQ: PSTV) (the “Company”), a healthcare company developing and commercializing…
-Initiation of phase 1 portion of the trial planned in 2H 2026 -Phase 2 portion of the trial will initiate…
Pathology data indicate 70% overall response rate for squamous cell carcinomas: 100% clearance in 10 out of 14 responders Favorable…